Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial
Advancing Access to Cell and Gene Therapies in Medicaid
18 June 2024
Milestone events in recessive dystrophic epidermolysis bullosa: findings from a prospective register study
1 July 2024
Advancing Access to Cell and Gene Therapies in Medicaid
18 June 2024
Milestone events in recessive dystrophic epidermolysis bullosa: findings from a prospective register study
1 July 2024

J Eur Acad Dermatol Venereol. 2024 Jul 1. doi: 10.1111/jdv.20189. Epub ahead of print. PMID: 38949042.

Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial

Authors: Utako Okata-Karigane 1 2Pirunthan Pathmarajah 1Emily S Gorell 3Katie Sum 1Kiana Yekrang 1Michelle Phung 1Melissa Barriga 1Patricia Udrizar 1 4Irene Bailey 1Shufeng Li 1 5Ying Lu 6Jean Y Tang 1Albert S Chiou 1

Affiliation:

  1. Department of Dermatology, Stanford University School of Medicine, Redwood City, California, USA.
  2. Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
  3. Dermatology Insights, LLC, Cincinnati, Ohio, USA.
  4. Research Management Group, Stanford University School of Medicine, Stanford, California, USA.
  5. Department of Urology, Stanford University School of Medicine, Stanford, California, USA.
  6. Department of Biomedical Data Science, Stanford School of Medicine, Stanford, California, USA.

Abstract:

No abstract available

Download: https://pubmed.ncbi.nlm.nih.gov/38949042/